Podcasts about lung disease

Albina Tyker, MD, and Kerri A. Johannson, MD, MPH, join CHEST® Journal Podcast Moderator Alice Gallo De Moraes, MD, FCCP, to discuss their research into the association between recovery time from exertional desaturation following a 6-minute walk test with disease severity and progression in patients with fibrotic interstitial lung disease. DOI: 10.1016/j.chest.2025.12.023 Disclaimer: The purpose of this activity is to expand the reach of CHEST content through awareness, critique, and discussion. All articles have undergone peer review for methodologic rigor and audience relevance. Any views asserted are those of the speakers and are not endorsed by CHEST. Listeners should be aware that speakers' opinions may vary and are advised to read the full corresponding journal article(s) for complete context. This content should not be used as a basis for medical advice or treatment, nor should it substitute the judgment used by clinicians in the practice of evidence-based medicine.  

This week, we begin a four-part series on the 5th-largest killer in America.  In this episode, you'll discover:—How COPD (Chronic Obstructive Pulmonary Disease) is responsible for the overwhelming majority of Chronic Lower Respiratory Disease (or CLRD) deaths.  And how Emphysema and Asthma are also included in this category. —Why Dr. Prather says it is "a major issue" to get patients (and sometimes their doctors) to take their shortness of breath seriously. —The devastating impact of cigarette smoking on CLRD.  And how Dr. Prather has seen young people whose Lungs have shut down even after just three months of vaping.—Why Dr. Prather says that marijuana can actually even be worse than cigarettes on the Lungs.—How Asthma can be a precursor of COPD and damages the Lungs over time.  Plus, the role of obesity in contributing to Lung problems and CLRD. —The influence of nutrition on Lung Disease and why Dr. Prather believes Fiber is the key. —The Alpha-1 antitrypsin generic factor that can be a root cause of Lung disease.  And how infections like Histoplasmosis can increase your risk of developing COPD.—The Spirometry Lung Function Test at Holistic Integration that reveals the health of your Lungs. —How you CAN improve the health of your Lungs and even regenerate your Lungs through Structure-Function Care. —Why Dr. Prather says how deep you breathe is the number one indicator of how long you will live. http://www.TheVoiceOfHealthRadio.com*Receive exclusive bonus content as a member of our Voice Of Health Patreon Community:https://www.patreon.com/cw/VoiceofHealthPodcast

Send us Fan MailIn this episode, we discuss drug induced ILD, reviewing its diagnostic criteria and management. Written by: Dr. Reenika Aggarwal. Reviewed by: Dr. Joshua Wald (Respirology) and Dr. Andrew Cheung (General Internal Medicine). Support the show

In this episode, Dr. Gerard Criner, Chair and Professor of Thoracic Medicine and Surgery at the Lewis Katz School of Medicine at Temple University and Director of the Temple Lung Center at Temple Health, shares how multidisciplinary collaboration, data driven infrastructure, and a focus on quality outcomes are driving growth and innovation in lung transplant care.This episode is sponsored by Temple Health.

Valerie Dehondt, PharmD, and Lies Lahousse, PharmD, PhD, join CHEST® Journal Podcast Moderator Gretchen Winter, MD, to discuss their research into the association between long-term proton pump inhibitor use and exacerbation risk in patients with chronic obstructive airway diseases.    DOI: 10.1016/j.chest.2026.01.002 Disclaimer: The purpose of this activity is to expand the reach of CHEST content through awareness, critique, and discussion. All articles have undergone peer review for methodologic rigor and audience relevance. Any views asserted are those of the speakers and are not endorsed by CHEST. Listeners should be aware that speakers' opinions may vary and are advised to read the full corresponding journal article(s) for complete context. This content should not be used as a basis for medical advice or treatment, nor should it substitute the judgment used by clinicians in the practice of evidence-based medicine.  

Dr. Mohleen Kang chats with Dr. Kerri Johannson and Dr. Tamera Corte about their article, "Impact of Environmental Exposures on the Development and Progression of Fibrotic Interstitial Lung Disease."

 April is Sarcoidosis Awareness Month! Host Patti Tripathi speaks with Mary McGowan, president and CEO of the Foundation for Sarcoidosis Research, about the importance of continuing research on sarcoidosis, advocacy and policy efforts in the field, and fighting for paid leave for those participating in clinical trials. Learn more about the Foundation for Sarcoidosis Research at https://www.stopsarcoidosis.org/ Learn more about The Champions for Change: https://site.thoracic.org/press-releases/champions-for-change-paid-time-off-initiative-just-made-clinical-trials-participation-easier Learn more about the bipartisan Congressional Sarcoidosis Caucus: https://gottheimer.house.gov/posts/release-gottheimer-launches-bipartisan-sarcoidosis-caucus-to-battle-the-debilitating-disease-in-memory-of-his-mother 

In this episode, Dr. Shervin Assassi discusses a secondary analysis of the SENSCIS trial, exploring how peripheral blood gene expression may predict response to mycophenolate in systemic sclerosis–associated lung disease. He highlights key findings linking immune and metabolic gene signatures, as well as C-reactive protein, to changes in lung function, and considers their potential role in guiding treatment and clinical trial design. The episode also touches on his career journey and insights into leadership, mentorship, and sustaining research productivity.  Peripheral Blood Gene Expression Profiling and Prognostic Significance for the Course of Interstitial Lung Disease in Patients With Systemic Sclerosis 

I'm excited to welcome back Dr. Elizabeth Volkmann. Dr. Volkmann takes a truly holistic approach to care, focusing on the whole person rather than just the disease. She also has a wonderful new Instagram page filled with helpful, informative content that you won't want to miss. As always, it was an absolute delight talking with her.

Full article: Quantitative CT Measurements of Interstitial Lung Disease: Same-Day Variability Between Two Vendors—A Prospective Study Longitudinal monitoring of interstitial lung disease (ILD) requires insight into the variability of quantitative ILD measurements. Dora Chen, MD, discusses the article by Ahn et al. reporting results of a prospective study in which patients with ILD underwent same-day chest CT examinations using scanners from different vendors.  

Please visit answersincme.com/860/240201375-replay to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by James Michael Ramsahai, BSc, MD, PhD, FRCPC and Nan Zhao, BSc, MD, FRCPC. In this activity, experts in managing severe eosinophilic asthma discuss evidence-based strategies for personalizing biologic therapy, reducing steroid burden, and optimizing treatment in the setting of overlapping eosinophilic diseases. Upon completion of this activity, participants should be better able to: Identify strategies to individualize the selection of biologic therapies for patients with severe eosinophilic asthma based on the latest clinical and real-world evidence; Evaluate the implications of real-world data on biologic therapies for addressing airway remodeling and airway plugging; Develop steroid-sparing treatment plans and monitoring strategies for patients with severe eosinophilic asthma; and Formulate treatment plans to adjust the use of biologic therapies in patients with severe eosinophilic asthma and overlapping eosinophilic comorbidities.

Please visit answersincme.com/860/240201375-replay to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by James Michael Ramsahai, BSc, MD, PhD, FRCPC and Nan Zhao, BSc, MD, FRCPC. In this activity, experts in managing severe eosinophilic asthma discuss evidence-based strategies for personalizing biologic therapy, reducing steroid burden, and optimizing treatment in the setting of overlapping eosinophilic diseases. Upon completion of this activity, participants should be better able to: Identify strategies to individualize the selection of biologic therapies for patients with severe eosinophilic asthma based on the latest clinical and real-world evidence; Evaluate the implications of real-world data on biologic therapies for addressing airway remodeling and airway plugging; Develop steroid-sparing treatment plans and monitoring strategies for patients with severe eosinophilic asthma; and Formulate treatment plans to adjust the use of biologic therapies in patients with severe eosinophilic asthma and overlapping eosinophilic comorbidities.

Dr. Mohleen Kang chats with Dr. Stephen Humphries, Dr. Matthew Koslow, Dr. Justin Oldham, Dr. Jennifer Wang, Alexander Bankier, and Dr. David Baraghoshi about their articles, "A Quantitative Imaging Measure of Progressive Pulmonary Fibrosis" and "One-Year Change in Quantitative Computed Tomography Is Associated with Meaningful Outcomes in Fibrotic Lung Disease."

Send a textEvening Prayer (Salvation; Lung Disease; Liver Disease; Pain; Unborn Children)Thank you for listening, our heart's prayer is for you and I to walk daily with Jesus, our joy and peace aimingforjesus.com YouTube Channel https://www.youtube.com/@aimingforjesus5346 Instagram https://www.instagram.com/aiming_for_jesus/ Threads https://www.threads.com/@aiming_for_jesus X https://x.com/AimingForJesus Tik Tok https://www.tiktok.com/@aiming.for.jesus

A cooking spray is linked to lung disease HR 4 full 2447 Thu, 12 Feb 2026 19:09:31 +0000 9wGHsL39E2gQNhOv4XbGEboEOS4lAraP news MIDDAY with JAYME & WIER news A cooking spray is linked to lung disease HR 4 From local news & politics, to what's trending, sports & personal stories...MIDDAY with JAYME & WIER will get you through the middle of your day! © 2025 Audacy, Inc. News False https://player.amperwavepodcasting.com?feed-li

Bronchopulmonary dysplasia affects up to 90% of extremely preterm infants, yet no approved therapies exist. In this episode of the In Vivo podcast, Airway Therapeutics CEO Marc Salzberg discusses how their Phase Ib study of zelpultide alfa, a recombinant surfactant protein D, showed substantial reductions in BPD incidence and mechanical ventilation time. Salzberg explains the unique challenges of running neonatal trials, navigating regulatory pathways for vulnerable populations, and why preventing BPD could unlock broader respiratory applications. From ethics and enrollment to EMA approval and global expansion, this episode explores what it takes to develop breakthrough medicines for the smallest, most fragile patients.

James Cheng Chung Wei, MD, PhD, and Po-Cheng Shih, MD, join CHEST® Journal Podcast Moderator Alice Gallo De Moraes, MD, FCCP, to discuss their research into the comparative effectiveness and safety of tocilizumab and rituximab in patients with rheumatoid arthritis-associated interstitial lung disease.   DOI: 10.1016/j.chest.2025.09.009 Disclaimer: The purpose of this activity is to expand the reach of CHEST content through awareness, critique, and discussion. All articles have undergone peer review for methodologic rigor and audience relevance. Any views asserted are those of the speakers and are not endorsed by CHEST. Listeners should be aware that speakers' opinions may vary and are advised to read the full corresponding journal article(s) for complete context. This content should not be used as a basis for medical advice or treatment, nor should it substitute the judgment used by clinicians in the practice of evidence-based medicine.  

When your child survives one medical emergency only to face another, parenting becomes a constant act of advocacy and courage. Today's guest joins us to share her daughter's journey with rare and complex medical conditions, from early respiratory failure and unexplained hospitalizations to epilepsy, lung disease, and life with medical uncertainty. As a military spouse navigating deployments, Brittany shares what it means to walk this path largely alone, trust her instincts as a mother, and fight to be believed by medical professionals. This episode explores navigating rare disease without clear answers, the life-changing impact of compassionate child life support, supporting siblings through medical trauma, and how rituals, play, and community help families find hope and meaning in the midst of chaos. Download our free Children's Hospital Passport to help empower your child and family during hospital stays. Sponsored in part by HealthWell Foundation—learn how you can help families afford life-saving medications at healthwellfoundation.org.   Resources from today's episode: Medical Support:  Stanford Children's Health  Undiagnosed Diseases Network Nonprofit & Community Support: Live Like JoJo Foundation The Meg Foundation (Pediatric Pain & Poke Plans)  Brave Bears Club (Epilepsy Support) Child Life Mommy CHYP  Connect with Brittany Follow Brittany's journey as she shares life as a medical mom, military spouse, and advocate.    Connect & Support from Child Life On Call  Subscribe: Never miss an episode on Apple Podcasts or Spotify. Visit insidethechildrenshospital.com to easily search stories and episodes Follow us on Instagram for updates and opportunities to connect with other parents Download SupportSpot: receive Child Life tools at your fingertips. Leave a Review: It helps other families find us and access our resources!   Keywords: Rare disease parenting, Medical motherhood, Medically complex child, Pediatric lung disease, Pediatric epilepsy, Intractable epilepsy, PICU parent experience, Military family healthcare, Parent advocacy in healthcare, Child life specialist support, Sibling support during hospitalization, Parenting after medical trauma, Coping with chronic illness, Undiagnosed disease journey, Hospital parent support Medical information provided is not a substitute for professional advice—please consult your care team  

Drs. Kaul and Adegunsoye discuss advanced technologies to improve early detection and treatment of interstitial lung disease in veterans, with innovative approaches including the MAVRIC trial and AI-powered risk prediction models. These efforts aim to transform pulmonary care by identifying high-risk patients and developing targeted interventions.

Drs. Kaul and Adegunsoye discuss Veterans Affairs' innovative approach to understanding and treating pulmonary fibrosis among veterans by leveraging extensive electronic health records and data repositories. The work focuses on addressing healthcare disparities, exploring risk factors, and developing a hub-and-spoke telehealth model to provide specialized care to veterans in rural and underserved areas.

Lose Fat With Personalized 1:1 Coaching HEREhttps://theclubhouse1.lpages.co/1to1-coaching On this episode, I sit down with one of our clients, Wes and Coach Irene to talk about one of the most inspiring comeback stories I've heard. Despite battling lung disease, neck surgery, and unimaginable personal loss, Wes started his transformation journey when he had every reason not to. We dive into how he lost 30 pounds, the power of small changes, and what it's like doing this journey alongside his partner. Free Calorie Calculator https://ericrobertsfitness.com/free-calorie-calculator/ 20% Off Legion Athletic Supplements Code “ERIC” HERE https://legionathletics.rfrl.co/qj2dy Youtube Channelhttps://www.youtube.com/@ericrobertsfitness

FOR MEDICAL PROFESSIONALS:SIGN UP FOR OUR FREE TRAINING Jan 10th! The Countertransference & Chronic Illness Intensive https://www.thechronicillnesstherapist.com/countertransference-chronic-illness-intensive

The lung Composite Allocation Score (CAS) was implemented in 2023, and has shown to increase lung transplant rates and lower waitlist mortality. Host Alice Gallo de Moraes, MD, of the Mayo Clinic, interviews experts Mary Raddawi, MD, of Columbia University Irving Medical Center, and Amy Skiba, of the Lung Transplant Foundation, on the importance of CAS and how it has changed outcomes for lung transplant patients. 

 This Giving Tuesday, we have a special episode of the ATS Breathe Easy podcast. Wildfires are a destructive phenomenon that decimates communities, infrastructure, and wildlife. But wildfires and wildfire smoke are also severely damaging to human health, especially for those who have lung disease. Stacie Reveles, of the Cystic Fibrosis Research Institute, talks about her struggles living in wildfire country with a child who has cystic fibrosis. She discusses everything from dealing with medications and evacuations, the mental toll, and the importance of continued research into these illnesses. Air Health Our Health podcast creator Erika Moseson, MD, MA, of Legacy Health in Oregon hosts. Donate to the ATS Research Program today to help families like Stacie's: https://aeugmntn.donorsupport.co/page/Stacie The ATS Wildfire Disaster Guidance sheet: https://www.thoracic.org/patients/patient-resources/resources/wildfires.pdf  Listen to the Our Health in Wildfire Season episode of Air Health Our Health for how to prepare your home and community: https://creators.spotify.com/pod/profile/airhealthourhealth/episodes/Our-Health-in-Wildfire-Season-e162en9/a-a2ata11 

Welcome to the emDOCs.net podcast! Join us as we review our high-yield posts from our website emDOCs.net.Today on the emDOCs cast with Brit Long (@long_brit), we cover management of AE-ILD exacerbations. For more on evaluation, take a listen to Part 1. To continue to make this a worthwhile podcast for you to listen to, we appreciate any feedback and comments you may have for us. Please let us know!Subscribe to the podcast on one of the many platforms below:Apple iTunesSpotifyGoogle Play

Prof Sailesh Kotecha joins Diana Stanley to discuss the series on reframing prematurity-associated lung disease as a continuum that begins before birth and evolves throughout life.Cick here to read the full series: Looking beyond bronchopulmonary dysplasia: prematurity-associated lung disease and its phenotypeshttps://www.thelancet.com/journals/lanres/article/PIIS2213-2600(25)00372-8/fulltextTrajectories of prematurity-associated lung disease: lifelong lung healthhttps://www.thelancet.com/journals/lanres/article/PIIS2213-2600(25)00371-6/fulltextManagement of prematurity-associated lung disease from infancy through to adulthoodhttps://www.thelancet.com/journals/lanres/article/PIIS2213-2600(25)00369-8/fulltextContinue this conversation on social!Follow us today at...https://thelancet.bsky.social/https://instagram.com/thelancetgrouphttps://facebook.com/thelancetmedicaljournalhttps://linkedIn.com/company/the-lancethttps://youtube.com/thelancettv

Send us a textIn this episode of At the Bench, Misty Good and David McCulley interview Dr. Bernard Thébaud, a neonatologist and leader in lung and pulmonary vascular developmental biology and regenerative medicine. The conversation explores Dr. Thebaud's journey into research, the importance of mentorship, and the challenges of translating research into clinical practice. They discuss the significance of recognizing opportunities, navigating critical feedback, and the promising mechanisms in regenerative medicine that could enhance lung repair in preterm infants. Dr. Thébaud discusses the innovative use of mesenchymal stromal cells in lung therapy for neonatal patients. He shares insights on the unexpected findings from his research, the potential of umbilical cord-derived cells, and the future of neonatal lung regenerative medicine. The conversation also touches on the importance of mentorship, resilience in research, and fostering a positive lab environment.Support the showAs always, feel free to send us questions, comments, or suggestions to our email: nicupodcast@gmail.com. You can also contact the show through Instagram or Twitter, @nicupodcast. Or contact Ben and Daphna directly via their Twitter profiles: @drnicu and @doctordaphnamd. The papers discussed in today's episode are listed and timestamped on the webpage linked below. Enjoy!

Welcome to the emDOCs.net podcast! Join us as we review our high-yield posts from our website emDOCs.net.Today on the emDOCs cast with Brit Long (@long_brit), we cover interstitial lung disease and exacerbations. In Part 1, we discuss some background, presentation, and the ED evaluation. Part 2 will cover management. To continue to make this a worthwhile podcast for you to listen to, we appreciate any feedback and comments you may have for us. Please let us know!Subscribe to the podcast on one of the many platforms below:Apple iTunesSpotifyGoogle Play 

The Triple Threat to the Rare Disease Ecosystem — A Conversation with Dr. Wendy ChungSometimes you come across someone whose work changes the way you think about an entire field. That's exactly what happened when I read about Dr. Wendy Chung in Rare Revolution Magazine.Dr. Chung is one of those rare people who stands at the intersection of science, medicine, ethics, and humanity. She's a clinical and molecular geneticist, the Chief of Pediatrics at Boston Children's Hospital, and the Mary Ellen Avery Professor at Harvard Medical School. She leads NIH-funded research into the genetics of conditions like pulmonary hypertension, autism, birth defects, and a wide range of rare diseases. She's advanced newborn screening for life-threatening disorders like spinal muscular atrophy and Duchenne muscular dystrophy — work that means the difference between life and death for many families. She's been recognized with the Rare Impact Award from NORD, is a member of the National Academy of Medicine, and is a leading voice on the ethics of genomics.But titles and accolades only tell part of her story. What stands out most is her deep commitment to the people behind the science, the families living day in and day out with conditions that most of the world has never heard of.When we spoke, Dr. Chung described what she calls the “triple threat” to the rare disease ecosystem:Misinformation in health that spreads faster than facts and erodes trust in science.Lack of access to healthcare, leaving too many without the treatments they need, when they need them.Insufficient investment in research, slowing the pace of discovery and delaying life-saving therapies.Each of these challenges is daunting on its own, but together they create a fragile and often hostile environment for progress in rare disease research and care.She pointed out that while most genetic conditions are rare individually, collectively they are surprisingly common — affecting millions worldwide. That's a staggering thought, especially considering how little public awareness and funding rare diseases often receive.We also talked about autism, a condition she has studied extensively. She emphasized that autism is a spectrum, with multiple causes, the majority of which are genetic. Understanding that complexity is crucial, not only for advancing science but also for helping families cope and make informed decisions.One of the threads running through our conversation was the urgent need for better communication in science. In an age where misinformation spreads in seconds, the ability to convey facts clearly and accessibly isn't just a nice skill — it's a necessity. Miscommunication or confusion doesn't just impact public opinion; it influences policy decisions, research funding, and the direction of healthcare itself.Dr. Chung stressed that advocacy matters at every level — from the conversations parents have with their children's doctors to the policies shaped in Washington. Community engagement isn't just a feel-good idea; it's one of the most effective ways to accelerate progress. Patients, families, scientists, and policymakers all have a role to play, and collaboration among them is where breakthroughs happen.In the end, our conversation left me with two truths. First, that rare disease progress depends on persistence from so many people. The researchers who refuse to give up, from families who continue to fight for answers, and from advocates who push for change. Second, that truth itself is a kind of medicine. The more accurately, compassionately, and consistently we can communicate about rare diseases, the better chance we have at building a healthcare ecosystem that works for everyone.Dr. Wendy Chung is leading that charge, not just in the lab, but in the public square. And in this fight, both matter equally. Please like, subscribe, and comment on our podcasts!Please consider making a donation: https://thebonnellfoundation.org/donate/The Bonnell Foundation website:https://thebonnellfoundation.orgEmail us at: thebonnellfoundation@gmail.com Watch our podcasts on YouTube: https://www.youtube.com/@laurabonnell1136/featuredThanks to our sponsors:Vertex: https://www.vrtx.comViatris: https://www.viatris.com/en

Screen RA ILD Properly  Rheumatoid Arthritis Highlights  Predicting Rheumatoid Arthritis  GDF-15: How Depression is Related to Lung Disease in RA 

GDF-15: How Depression is Related to Lung Disease in RA  What Can we do About Chronic Pain?  What's the latest in PsA?  What to do after first TNR failure in axSpA? 

Please visit answersincme.com/860/96036801-replay to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, experts in nontuberculous mycobacterial lung disease discuss the latest in diagnosis and optimized management of Mycobacterium avium complex (MAC) lung disease. Upon completion of this activity, participants should be better able to: Describe strategies to assess suspected nontuberculous mycobacterial (NTM) lung disease; Review guideline-recommended treatment plans for Mycobacterium avium complex (MAC) lung disease; Explain the clinical significance of the latest evidence for emerging first-line therapies for MAC lung disease, in the context of current standard of care; and Outline best practices to enhance outcomes for patients with MAC lung disease, including those receiving approved or emerging first-line therapies.

Please visit answersincme.com/860/96036801-replay to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, experts in nontuberculous mycobacterial lung disease discuss the latest in diagnosis and optimized management of Mycobacterium avium complex (MAC) lung disease. Upon completion of this activity, participants should be better able to: Describe strategies to assess suspected nontuberculous mycobacterial (NTM) lung disease; Review guideline-recommended treatment plans for Mycobacterium avium complex (MAC) lung disease; Explain the clinical significance of the latest evidence for emerging first-line therapies for MAC lung disease, in the context of current standard of care; and Outline best practices to enhance outcomes for patients with MAC lung disease, including those receiving approved or emerging first-line therapies.

STOP RA Cellular & Serologic Predictors Is AI Smarter than a Doctor? Lung Disease in ANCA-associated Vasculitis  Older Adults Underrepresented in RCTs  Next Generation T-Cell Engager: The Future Lupus in Focus: 2025 ACR Treatment Guidelines for SLE  Psoriatic Arthritis Imaging   

From our first breath, the air we breathe and our genes shape how our lungs function. It's a complex interplay we began exploring in our season four episode “Take A Deep Breath: Treating Asthma.” Today, we're branching out to discuss lung biology and the diseases that make it difficult to breathe. In this episode, co-host Maria Wilson speaks with Dorothy Cheung, Executive Group Medical Director, and Daniel Lafkas, Senior Principal Scientist, Translational Discovery Research, Roche, to understand how conditions with unmet need like chronic bronchitis and emphysema disrupt lung function. They discuss the challenges to treating lung diseases and explore promising approaches, from cutting-edge imaging technologies that help researchers uncover early drivers of disease, to treatments aimed at stopping the loss of lung function and restoring it. Read the full text transcript at www.gene.com/stories/decoding-lung-disease

How I Survived Meth Addiction, Lung Failure, and Found Purpose Anthony Carrasco was a meth addict by 15, and nearly dead by 35. Diagnosed with PH after years of drug use, his story spiraled from homelessness to hospice. But a double lung transplant and a deep surrender to recovery transformed everything. This Special Edition Episode Sponsored by: Johnson & Johnson Learn more about pulmonary hypertension trials at www.phaware.global/clinicaltrials. Follow us on social @phaware Engage for a cure: www.phaware.global/donate #phaware Share your story: info@phaware.com @JNJInnovMed

Treating Meth-Associated PAH Without Judgment Dr. Brandon Jakubowski takes us into the underrecognized world of stimulant-induced pulmonary arterial hypertension. From misdiagnoses to under-prescribing life-saving therapies, he lays out the systemic gaps and stigmas preventing patients from getting the care they need. This Special Edition Episode Sponsored by:  Johnson & Johnson Learn more about pulmonary hypertension trials at www.phaware.global/clinicaltrials. Follow us on social @phaware Engage for a cure: www.phaware.global/donate #phaware Share your story: info@phaware.com #phawareMD @JNJInnovMed @UTSWMedCenter

The Face of Addiction Isn't Who You Think It Is Once thought to be a West Coast issue, methamphetamine-associated pulmonary hypertension is now a nationwide and global crisis. Dr. Nicholas Kolaitis reveals how building trust with meth associated-PAH patients can lead to incredible turnarounds, including sobriety, trial participation, and successful transplant. This Special Edition Episode Sponsored by: Johnson & Johnson Learn more about pulmonary hypertension trials at www.phaware.global/clinicaltrials. Follow us on social @phaware Engage for a cure: www.phaware.global/donate #phaware Share your story: info@phaware.com @JNJInnovMed #PHawareMD @UCSFHospitals @LungTxptMD

Kenny Kasnett, a seasoned executive and entrepreneur whose life took an unexpected turn with a diagnosis of interstitial lung disease (ILD) joins the podcast for a powerful episode. What began as a persistent cough during a round of golf soon unraveled into a life-threatening condition that would ultimately require a lung transplant. Kenny opens up about the diagnostic journey, the emotional toll of living with ILD, and the difficult road leading up to transplant surgery. He shares a behind-the-scenes look at the complexities of preparing for and receiving a lung transplant, from waiting on the national registry to the moment he received the life-changing call. But Kenny's story is more than medical, it's about resilience, gratitude, and the extraordinary gift of a second chance at life. He speaks candidly about the pain, fear, and vulnerability he faced along the way, and how he leaned on the unwavering support of family, friends, and a stellar medical team. We also explore the long-term realities of transplant recovery, from managing medications and monitoring for rejection to navigating new physical limitations with hope and strength. Kenny's insights offer a beacon of light for others navigating lung disease and chronic illness. Topics Covered: Early signs and diagnosis of interstitial lung disease (ILD) Understanding ILD and idiopathic pulmonary fibrosis (IPF) Emotional and physical impact of progressive lung failure Choosing a lung transplant center and navigating evaluations The day of the transplant: fears, preparations, and gratitude Recovery and rehab: from ICU to walking again Long-term care, medications, and monitoring for rejection How this journey reshaped Kenny's perspective on life Advice for newly diagnosed patients and caregivers The importance of organ donation and honoring the donor Guest Bio: Kenny Kasnett is an accomplished business leader with decades of experience in finance, homebuilding, and real estate. Beyond his professional roles, Kenny is a lung transplant recipient and fierce advocate for those living with interstitial lung disease. Through his story, Kenny offers hope, encouragement, and critical insights into navigating serious illness with courage and grace. Resources & Links: Learn more about Interstitial Lung Disease (American Lung Association) National Jewish Health - Interstitial Lung Disease (ILD) Program Organ Donor Registration – Donate Life During the interview, Beth referenced a previous episode of It Happened To Me where the inspiring Zach Ship shared about his experience of getting a kidney transplant, this was Episode #44. The following episode (#45) Zach joined us again to talk about his other medical challenge, experiencing blindness before the age of 30.    Stay tuned for the next new episode of “It Happened To Me”! In the meantime, you can listen to our previous episodes on Apple Podcasts, Spotify, streaming on the website, or any other podcast player by searching, “It Happened To Me”.    “It Happened To Me” is created and hosted by Cathy Gildenhorn and Beth Glassman. DNA Today's Kira Dineen is our executive producer and marketing lead. Amanda Andreoli is our associate producer. Ashlyn Enokian is our graphic designer.   See what else we are up to on Twitter, Instagram, Facebook, YouTube and our website, ItHappenedToMePod.com. Questions/inquiries can be sent to ItHappenedToMePod@gmail.com. 

In this episode, our guests Dr. Sabrina Hoa and Dr. Marie Hudson explore new insights into late-onset interstitial lung disease (ILD) in scleroderma. Using data from the Canadian Scleroderma Research Group, they discuss how ILD can still develop years after diagnosis, challenging traditional screening timelines. They cover key findings, clinical implications, treatment patterns, and the need for more inclusive trials. The conversation also touches on mentorship and what's next in scleroderma research. 

How Stigma Blocks Meth-PAH Treatment and How to Stop It Patients with methamphetamine-associated-PAH often arrive at clinics already carrying heavy shame. But shame shouldn't be part of their medical history. In this compelling episode, Dr. Peter Leary explains how stigma—from both society and providers—can delay life-saving care. Learn how a change in mindset, language, and compassion can transform outcomes for a neglected and growing patient population. This Special Edition Episode Sponsored by: Johnson & Johnson Learn more about pulmonary hypertension trials at www.phaware.global/clinicaltrials. Follow us on social @phaware Engage for a cure: www.phaware.global/donate #phaware Share your story: info@phaware.com #phawareMD @uwepidemiology  @JNJInnovMed

The Hidden Epidemic: Meth and PHMeth-Associated PAH is on the rise across the United States, yet many patients are not receiving the treatment they need. Dr. Vinicio de Jesus Perez discusses the shifting demographics of meth users, the challenges of treating addiction in cardiopulmonary care, and the need for compassionate, stigma-free screening. This Special Edition Episode Sponsored by: Johnson & Johnson Learn more about pulmonary hypertension trials at www.phaware.global/clinicaltrials. Follow us on social @phaware Engage for a cure: www.phaware.global/donate #phaware Share your story: info@phaware.com #phawareMD @PHatStanford  @Viniciodjperez  @JNJInnovMed

Dr. John Kingrey exposes the rising crisis of meth-associated pulmonary hypertension, a condition spreading fast across the U.S. He challenges misconceptions, highlights urgent research, and stresses the need for compassion in treating both PAH and addiction. This Special Edition Episode Sponsored by: Johnson & Johnson Learn more about pulmonary hypertension trials at www.phaware.global/clinicaltrials. Engage for a cure: www.phaware.global/donate #phaware Share your story: info@phaware.com Like, Subscribe and Follow us: www.phawarepodcast.com. @integrishealth @teamphhope @JNJInnovMed #phawareMD

Delays in diagnosing and treating pulmonary hypertension (PH) can have life-altering consequences. In this episode, Dr. Kari Gillmeyer, discusses her groundbreaking study on PH care networks. She explores why so many patients experience delays, how geography and provider access play a role, and what can be done to improve timeliness of care. This Special Edition Episode Sponsored by: Johnson & Johnson Learn more about pulmonary hypertension trials at www.phaware.global/clinicaltrials. Engage for a cure: www.phaware.global/donate #phaware Share your story: info@phaware.com Like, Subscribe and Follow us: www.phawarepodcast.com. @VABostonHC @The_BMC @JNJInnovMed

A 200 Mile Journey from LA to San Diego to Raise Awareness for PH When Eric Borstein collapsed in his bedroom in 2020, doctors gave him just months to live. Instead, he fought back with walking, mental health, and the support of his community. Now, he's leading a movement, raising hundreds of thousands for pulmonary hypertension research, and walking 200 miles down the California coast to prove hope has no limits. Learn more about the 2nd Annual Where is EB? 5K Walk and Fundraiser September 7, 2025 Learn more about pulmonary hypertension trials at www.phaware.global/clinicaltrials. Follow us on social @phaware  Engage for a cure: www.phaware.global/donate #phaware Share your story: info@phaware.com @teamphhope  @where_is_eb @DJLisaFoxx  

Send us a textIn this episode of At-the-Bench, hosts David McCulley and Misty Good interview Dr. Jennifer Wambach, a neonatologist and researcher specializing in rare neonatal lung diseases. Dr. Wambach shares her journey into neonatology, her research on genetic lung diseases, and the importance of mentorship in developing future physician-scientists. The conversation also covers the Undiagnosed Diseases Network, current research on genetic lung diseases including ABCA3 deficiency, and the challenges faced in rare disease research. Dr. Wambach emphasizes the need for resilience and adaptability in scientific careers, offering valuable advice for early-career investigators.Support the showAs always, feel free to send us questions, comments, or suggestions to our email: nicupodcast@gmail.com. You can also contact the show through Instagram or Twitter, @nicupodcast. Or contact Ben and Daphna directly via their Twitter profiles: @drnicu and @doctordaphnamd. The papers discussed in today's episode are listed and timestamped on the webpage linked below. Enjoy!

In this episode, Dr. Akshay Muralidhar, Co-Director of the Pulmonary Hypertension Center of Excellence at Arizona Pulmonary Specialist in Phoenix, discusses the importance of having a specialized center for pulmonary hypertension. Dr. Muralidhar also highlights the challenges of managing patients with substance abuse issues, particularly methamphetamine use. Dr. Muralidhar emphasizes the importance of access to care, particularly for underserved communities, and the need for outreach programs to ensure that all patients have access to treatment options.  This Special Edition Episode Sponsored by: Johnson & Johnson Learn more about pulmonary hypertension trials at www.phaware.global/clinicaltrials. Follow us on social @phaware Engage for a cure: www.phaware.global/donate #phaware Share your story: info@phaware.com #phawareMD @JNJInnovMed

Dr. Raj Parikh from Hartford Hospital discusses building on foundational pathways with treatment options for Pulmonary Arterial Hypertension (PAH) patients. He also emphasizes the value of clinical trials as well as the importance of a good doctor/patient relationship.  This Special Edition Episode Sponsored by: Johnson & Johnson Learn more about pulmonary hypertension trials at www.phaware.global/clinicaltrials. Engage for a cure: www.phaware.global/donate #phaware Share your story: info@phaware.com Like, Subscribe and Follow us: www.phawarepodcast.com. #phawareMD @HartfordHealthC @JNJInnovMed

Dr. Robert Frantz breaks down the key metrics behind risk stratification—functional class, six-minute walk distance, and brain natriuretic peptide levels—and explains how they shape treatment plans. He also explores the role of echocardiography, right heart catheterization, and cutting-edge therapies in improving patient outcomes. Read the proceedings of the Task Force on Risk Stratification from the Seventh World Symposium on Pulmonary Hypertension.  This Special Edition Episode Sponsored by: Johnson & Johnson Learn more about pulmonary hypertension trials at www.phaware.global/clinicaltrials. Follow us on social @phaware Engage for a cure: www.phaware.global/donate #phaware Share your story: info@phaware.com #phawareMD #RiskStratification @MayoClinic @MayoMedEd @TeamPHHope @JNJInnovMed

Story at-a-glance Chronic respiratory diseases remain profitable but poorly treated, subjecting patients to expensive healthcare, impaired stamina, and painful decline DMSO is an "umbrella remedy" treating diverse ailments through therapeutic properties including reducing inflammation, improving circulation, and reviving dying cells These properties uniquely address underlying causes of chronic respiratory diseases by reducing fibrosis and inflammation, restoring damaged organs, and improving circulation DMSO addresses respiratory infections through antimicrobial activity, reduced lung inflammation, and potentiation of antimicrobial therapies Extensive published data and user reports demonstrate DMSO's remarkable results for asthma, COPD, cystic fibrosis, interstitial lung disease, pulmonary fibrosis, and pneumonia, including cases in which transplant was no longer necessary due to significant organ recovery